Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342714 | 0.85 | KMT2A (0.56) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL4077813 | 0.84 | KMT2A (0.55) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL391928 | 0.81 | CYP1A2 (0.53) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL17296652 | 0.80 | KMT2A (0.51) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL395590 | 0.80 | CYP1A2 (0.52) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL29034585 | 0.80 | CYP1A2 (0.49) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL3978103 | 0.80 | LMNA (0.58) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL4927181 | 0.80 | CYP1A2 (0.62) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL344623 | 0.79 | KMT2A (0.53) | KMT2AMEN1CYP1A2GAAESR1 | |
| SCHEMBL1889216 | 0.79 | LMNA (0.45) | KMT2AMEN1GAAGFERALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | AmDerma Pharmaceuticals, LLC (US) | 2019-10-08 | — | — | US | claimed |
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2019-06-27 | — | — | US | claimed |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | AmDerma Pharmaceuticals, LLC (US) | 2019-05-07 | — | — | US | claimed |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | ACTION MEDICINES, S.L. (ES) | 2018-02-08 | — | — | US | claimed |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | AmDerma Pharmaceuticals, LLC | 2018-02-01 | — | — | US | claimed |
| US-20160008303-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | AmDerma Pharmaceuticals, LLC | 2016-01-14 | — | — | US | claimed |
| US-9198886-B2 | Use of 2,5-dihydroxybenzene for the treatment of ocular diseases | CUEVAS SÁNCHEZ PEDRO (ES) | 2015-12-01 | — | — | US | claimed |
| US-9018195-B2 | Use of 2,5-dihydroxybenzene sulfonic acid compounds for treating skin photoaging | AmDerma Pharmaceuticals, LLC (US) | 2015-04-28 | — | — | US | claimed |
| US-20140328778-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | ACTION MEDICINES, S.L. (ES) | 2014-11-06 | — | — | US | claimed |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC | 2014-11-06 | — | — | US | claimed |
| WO-2008020039-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATING CANCERS AND HEMATOLOGICAL DYSCRASIAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020030-A1 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF PSORIASIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020028-A1 | 2,5 DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020031-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ANGIOGENIC DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020037-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING OBESITY, HIRSUTISM, HYPERTRICOSIS AND VIRAL WARTS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020040-A2 | 2,5-DIHYDROXYBENZENE COMPOUNDS FOR THE TREATMENT OF FIBROSIS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020034-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF HEMANGIOMAS OR HEMANGIOBLASTOMAS | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020033-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020032-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020042-A1 | USE OF 2, 5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF TISSUE REACTIVE DISEASES | ACTION MEDICINES, S.L. (ES) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192473-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KMT2A 1430/4885MEN1 4154/4885CYP1A2 4/4885 |
| US-20140328823-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | KMT2A 878/4885MEN1 2956/4885CYP1A2 52/4885 |
| US-20140328778-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP24A1, CYP8B1, CYP26B1 | KMT2A 1028/4885MEN1 4661/4885CYP1A2 46/4885 |
| US-10434076-B2 | Use of 2,5-dihydroxybenzene derivatives for treating dermatitis | CYP24A1, CYP8B1, CYP26B1 | KMT2A 1028/4885MEN1 4661/4885CYP1A2 46/4885 |
| US-20180036265-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP24A1, CYP8B1, CYP26B1 | KMT2A 1028/4885MEN1 4661/4885CYP1A2 46/4885 |
| US-20160008303-A1 | Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis | CYP8B1, CYP24A1, CYP26B1 | KMT2A 1110/4885MEN1 4463/4885CYP1A2 53/4885 |
| US-20180028484-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea | CYP8B1, CYP1B1, CYP26B1 | KMT2A 1430/4885MEN1 4154/4885CYP1A2 4/4885 |
| US-10278941-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma | ALDH1A2, IDH3A, IDH3B | KMT2A 678/4885MEN1 1130/4885CYP1A2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.